Gertjan Bartlema News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Immodulon to Participate in the Wells Fargo Virtual Private Biotech Symposium

Immodulon to Participate in the Wells Fargo Virtual Private Biotech Symposium
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomWilliam gramigJosh rappaportGertjan bartlemaPeter greaneyStern investor relations incWells fargoWells fargo virtual private biotechChief executive officerChief business officerWells fargo virtual private biotech symposiumInvestor relations

Immodulon Further Strengthens Leadership Team with the Appointments of Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer

Immodulon Further Strengthens Leadership Team with the Appointments of Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomFrazer hallOwen vaughanEleanor perkinGertjan bartlemaJosefine roemmler zehrerPeter greaneySandi greenwoodAlnylam pharmaceuticalsResearch scientistImmodulonfurther strengthens leadership teamRegulatory affairs quality assuranceOhio universityLehigh universityImmodulon therapeutics ltd

US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease

US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease VICO Therapeutics, a Leiden Bio Science Park, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan Products Development (OOPD) of the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for VO659, VICO s investigational antisense oligonucleotide (AON) therapy, for the treatment of Huntington s disease (HD). This news comes only one month after VICO announced that VO659 had received orphan-drug designation for the treatment of spinocerebellar ataxia (SCA). This new designation completes the quartet of orphan designations for VO659 in HD and SCA in both the US and EU.

Noord hollandKostenloser wertpapierhandelRupert sandbrinkGertjan bartlemaDrug administrationLifespring life sciences communicationOffice of orphan products developmentLeiden bio science parkOrphan products developmentChief medical officerOrphan drug designationHuntington diseaseChief executive officerSpring life sciences communicationநூற்த் ஹாலண்ட்ஆயுட்காலம் வாழ்க்கை அறிவியல் தொடர்பு

US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia

US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Noord hollandKostenloser wertpapierhandelGertjan bartlemaEuropean commissionDrug administrationLifespring life sciences communicationOffice of orphan products developmentOrphan products developmentChief medical officerOrphan drug designationChief executiveSpring life sciences communicationHuntington diseaseநூற்த் ஹாலண்ட்ஐரோப்பிய தரகுஆயுட்காலம் வாழ்க்கை அறிவியல் தொடர்பு

European Commission grants Vico Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia

European Commission grants Vico Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia News provided by Share this article a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the European Commission (EC) has granted orphan drug designation for VO659, Vico s investigational antisense oligonucleotide therapy for the treatment of Spinocerebellar Ataxia (SCA). The orphan designation was based on a positive opinion from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP). Vico previously received orphan drug designation for VO659 in Huntington Disease. Spinocerebellar Ataxias

Noord hollandSpinocerebellar ataxiasJudith van deutekomRupert sandbrinkGail mandelPureos bioventuresLuc dochezGertjan bartlemaJosh mandel brehmCommittee for orphan medicinal productsEuropean unionEuropean medicines agencyEuropean commissionLifespring life sciences communicationSpinocerebellar ataxiaOrphan medicinal products